Side-by-side · Research reference

PEG-MGFvsTirzepatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED2/69 cited

BFDA-ApprovedFlagship14/45 cited

PEG-MGF

IGF-1Ec Splice Variant · PEGylated

~2 hrHalf-life (PEG)

~7 minNative MGF t½

IGF-1EcSplice variant

SQ · Research Protocol

Tirzepatide

GIP+GLP-1 Dual Agonist · FDA-Approved

2.5–15 mgWeekly doseZEPBOUND (tirzepatide) injecti 2023

20.9%Body-weight ↓Jastreboff 2022

~5 daysHalf-lifeZEPBOUND (tirzepatide) injecti 2023

SQ · Abdomen / thigh / arm · Once weekly

01Mechanism of Action

Parameter

PEG-MGF

Tirzepatide

Primary target

IGF-1 receptor on muscle satellite cells and myocytes

GIP receptor (GIPR) + GLP-1 receptor (GLP-1R)Frias 2018

Pathway

IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion

Dual GIPR/GLP-1R agonism → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↓appetite, ↑energy expenditure (via GIP component)Jastreboff 2022 Frias 2018

Downstream effect

Satellite cell activation, muscle fiber repair, localized hypertrophy signaling

Profound glycemic improvement and weight reduction; cardiometabolic benefitsJastreboff 2022

Feedback intact?

Partially bypassed — does not require hepatic IGF-1 synthesis

Glucose-dependent insulin release preserves physiological feedback

Origin

IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation

39-AA peptide with C-20 fatty-acid acylation. Single molecule with balanced GIP + GLP-1 affinityFrias 2018

Antibody development

Unknown — no long-term human immunogenicity data

—

02Dosage Protocols

Parameter

PEG-MGF

Tirzepatide

Research dose range

100–200 mcg

Extrapolated from animal models; no validated human protocols.

—

Frequency

Post-training or daily

Timing to match endogenous MGF pulse post-exercise.

—

Half-life

~2 hours (PEGylated)

Native MGF: ~7 min; PEGylation extends circulation.

~5 days (116 h)ZEPBOUND (tirzepatide) injecti 2023

Evidence basis

Animal / mechanistic

FDA-approved · Phase 3 RCTs (SURMOUNT, SURPASS)Jastreboff 2022 ZEPBOUND (tirzepatide) injecti 2023

Reconstitution

Sterile bacteriostatic water

Lyophilized form; store reconstituted at 2–8 °C.

Pre-filled commercial pen. Research vial: bacteriostatic water per label.

PEG molecular weight

Typically 5–30 kDa

Higher MW = longer t½, greater steric hindrance.

—

Timing

Within 30–60 min post-training

Aligns with endogenous MGF window.

Once weekly, any time of day

Standard dose (T2D)

—

5–15 mg / weekZEPBOUND (tirzepatide) injecti 2023

Standard dose (weight)

—

5, 10, or 15 mg / week (titrated)ZEPBOUND (tirzepatide) injecti 2023 Jastreboff 2022

Titration schedule

—

2.5 mg → +2.5 mg every 4 weeks → 15 mg max

Slower titration mitigates GI side effects.

Duration

—

Indefinite for chronic indication

03Metabolic / Fat Loss Evidence

Parameter

PEG-MGF

Tirzepatide

Primary target

Muscle tissue (satellite cells, myocytes) — not adipose-specific

—

Indirect metabolic effect

IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015

Mechanism distinct from direct lipolytic peptides.

—

Body composition

Lean mass preservation / hypertrophy focus

—

Fat loss evidence

No direct human or animal RCT data for PEG-MGF-driven fat reduction

—

04Side Effects & Safety

Parameter

PEG-MGF

Tirzepatide

Injection site reaction

Erythema, induration (common with SQ peptides)

Mild erythema, pruritus

Hypoglycemia risk

IGF-1 axis activation can lower blood glucose

—

IGF-1R overstimulation

Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure

—

Fluid retention

Possible with IGF-1 pathway activation (dose-dependent)

—

PEG accumulation

Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment

—

Antibody formation

PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)

—

Cancer risk

IGF-1 axis stimulation contraindicated in active malignancy

—

Human safety data

Absent — no published human trials for PEG-MGF

—

GI symptoms

—

Nausea, vomiting, diarrhea (common, dose-dependent)Jastreboff 2022

Pancreatitis risk

—

Rare; discontinue if suspectedZEPBOUND (tirzepatide) injecti 2023

Thyroid C-cell tumours

—

Boxed warning — contraindicated in MEN2 / MTC historyZEPBOUND (tirzepatide) injecti 2023

Hypoglycemia

—

Low as monotherapy; risk with sulfonylureas / insulin

Gallbladder events

—

Increased cholelithiasis

Pregnancy / OB

—

Contraindicated

Diabetic retinopathy

—

Rapid glycemic improvement may transiently worsen

Absolute Contraindications

PEG-MGF

·Active malignancy or history of cancer (IGF-1R proliferative signaling)
·Known hypersensitivity to PEGylated compounds
·Pregnancy / lactation (no reproductive toxicity data)

Tirzepatide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to tirzepatide

Relative Contraindications

PEG-MGF

·Diabetes (monitor glucose closely)
·Renal impairment (PEG clearance reduced)
·Retinopathy (IGF-1 axis effects on vascular proliferation)

Tirzepatide

·Severe gastroparesis
·History of pancreatitis
·Diabetic retinopathy

05Administration Protocol

Parameter

PEG-MGF

Tirzepatide

1. Reconstitution

Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.

Commercial: pre-filled pen / vial. Research lyophilised: bacteriostatic water per label.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.

SQ — abdomen, thigh, or upper arm. Rotate weekly.

3. Timing

Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.

Once weekly, same day. Day change allowed if ≥3 days separate doses.

4. Storage

Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.

Refrigerate 2–8 °C unopened. Room temp ≤30 °C up to 21 days after first use.

5. Needle

29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.

Pen-supplied. Research vial: 27–31G insulin syringe.

06Stack Synergy

PEG-MGF

+ BPC-157

Moderate

View BPC-157 →

BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.

PEG-MGF: 100–200 mcg SQ post-training
BPC-157: 250–500 mcg SQ or oral, twice daily
Duration: 4–6 weeks (injury-dependent)
Primary benefit: Accelerated muscle and connective tissue repair, enhanced recovery

+ TB-500

Strong

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.

PEG-MGF: 100–200 mcg SQ post-training
TB-500: 2–5 mg SQ, 2× per week (loading), then weekly
Timing: Stagger injections by 6–12 hours
Primary benefit: Maximal satellite cell recruitment and myogenic differentiation, injury repair

Tirzepatide

— no documented stacks